Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database

• Pierre-Marie Morice,
• Sabine Khalife-Hachem,
• Marion Sassier,
• Véronique Lelong-Boulouard,
• Alina Danu,
• Florence Pasquier,
• Aline Renneville,
• Charles Dolladille,
• Jean-Baptiste Micol

Affiliations

Pierre-Marie Morice

Department of Pharmacology, Caen-Normandy University Hospital

Sabine Khalife-Hachem

Department of Hematology, Gustave Roussy, Université Paris-Saclay

Marion Sassier

Department of Pharmacology, Caen-Normandy University Hospital

Véronique Lelong-Boulouard

Department of Pharmacology, Caen-Normandy University Hospital

Alina Danu

Department of Hematology, Gustave Roussy, Université Paris-Saclay

Florence Pasquier

Department of Hematology, Gustave Roussy, Université Paris-Saclay

Aline Renneville

INSERM U1287, Gustave Roussy, Université Paris-Saclay

Charles Dolladille

Normandie Univ, UNICAEN, INSERM U1086 ‘Interdisciplinary Research Unit for Cancers Prevention and Treatment’ (ANTICIPE)

Jean-Baptiste Micol

Department of Hematology, Gustave Roussy, Université Paris-Saclay